Novartis collaborates with Incyte with initiation plan of clinical study of Jakavi in COVID-19 patients Medical Dialogues Bureau6 April 2020 9:54 AM GMTBasel: Novartis has announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib)...
Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitung Medical Dialogues Bureau30 March 2020 7:49 AM GMTZurich: Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit's malaria, lupus and arthritis drug hydroxychloroquine is the company's...
Novartis, Life sciences companies commit to fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation Medical Dialogues Bureau29 March 2020 6:49 AM GMTBasel: Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture, and...
Novartis receives Japanese approval for Zolgensma for spinal muscular atrophy Medical Dialogues Bureau22 March 2020 6:15 AM GMTZolgensma is a one-time gene therapy designed to address the genetic root cause of the disease by replacing the function of the missing or nonworking...
Novartis updates on uses and safety of Beovu in patients with wet AMD Medical Dialogues Bureau3 March 2020 4:30 AM GMTIf clinical signs of intraocular inflammation or changes in vision after Beovu injection are observed doctor should perform the appropriate diagnostic...
Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list Medical Dialogues Bureau29 Nov 2019 3:45 AM GMTSeventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab,...
Pfizer, Novartis lead USD 2 billion spending spree on gene therapy production Medical Dialogues Bureau28 Nov 2019 3:30 AM GMTNew Delhi: Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018,...
Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal Medical Dialogues Bureau26 Nov 2019 4:00 AM GMTIn September 2018, the USD three billion drug-maker, Aurobindo Pharma said its US subsidiary entered into an agreement to acquire commercial...
Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020 Medical Dialogues Bureau26 Nov 2019 3:58 AM GMTRoche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
Novartis gets U.S. nod for long-delayed copycat version of Amgen billion seller Neulasta drug Medical Dialogues Bureau6 Nov 2019 5:02 AM GMTZURICH: Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in...
Another delay in USD 2.1 million gene therapy Zolgensma data reporting, Novartis admits mistake Medical Dialogues Bureau3 Nov 2019 4:15 AM GMTThe USFDA on Wednesday placed a partial hold on a Novartis trial of the $2.1 million-per-patient gene therapy, Zolgensma after the company informed...
SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns Medical Dialogues Bureau31 Oct 2019 4:15 AM GMTNovartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
